Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.57 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195555 | 1.00 | USP30 (0.57) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL3195542 | 1.00 | USP30 (0.57) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL3201649 | 1.00 | USP30 (0.57) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL3195548 | 1.00 | USP30 (0.57) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL2240156 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL953505 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL2239870 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL953506 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL2244835 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 | |
| SCHEMBL14400171 | 0.93 | TACR1 (0.61) | USP30TACR1PDE4BRORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | USP30 2995/4885TACR1 1028/4885PDE4B 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.